PMID- 15987622
OWN - NLM
STAT- MEDLINE
DCOM- 20060504
LR  - 20191109
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 7
IP  - 4
DP  - 2005 Jul
TI  - Direct thrombin inhibitors.
PG  - 255-9
AB  - Direct thrombin inhibitors (DTIs) are a new class of therapeutics possessing 
      theoretic advantages over unfractionated heparin (UFH). In contrast to UFH, DTIs 
      do not activate platelets, have no circulating inhibitors, and bind to both free 
      and clot-bound thrombin. These theoretical advantages have spurred clinical 
      trials investigating DTIs in a variety of cardiovascular indications. Currently, 
      the major role for DTIs in cardiology is as an adjunct during percutaneous 
      coronary intervention (PCI). Such a role stems from the results of the Randomized 
      Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 
      randomized trial, in which bivalirudin with provisional abciximab was 
      demonstrated to be equivalent to UFH plus planned abciximab with respect to 
      ischemic endpoints, while being associated with less bleeding. Ongoing clinical 
      trials will define the role of bivalirudin as an adjunct to primary PCI for 
      ST-segment elevation myocardial infarction and in non-ST segment elevation acute 
      coronary syndrome as an adjunct to an early invasive strategy.
FAU - Chen, Michael S
AU  - Chen MS
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 
      44195, USA.
FAU - Lincoff, A Michael
AU  - Lincoff AM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - NA8320J834 (Eptifibatide)
RN  - TN9BEX005G (bivalirudin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - *Angioplasty, Balloon, Coronary
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Coronary Disease/*drug therapy/therapy
MH  - Eptifibatide
MH  - Heparin/therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Peptide Fragments/*therapeutic use
MH  - Peptides/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins/therapeutic use
RF  - 21
EDAT- 2005/07/01 09:00
MHDA- 2006/05/05 09:00
CRDT- 2005/07/01 09:00
PHST- 2005/07/01 09:00 [pubmed]
PHST- 2006/05/05 09:00 [medline]
PHST- 2005/07/01 09:00 [entrez]
AID - 10.1007/s11886-005-0046-y [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2005 Jul;7(4):255-9. doi: 10.1007/s11886-005-0046-y.